Sopharma AD-Sofia (FRA:3JR) Non Operating Income: €0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3JR Sopharma AD-Sofia FRA:3JR
70 GF Score
Price €2.42
GF Value €1.90
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Non Operating Income?

Sopharma AD-Sofia FRA:3JR 70 Non Operating Income is €0 Mil as of Jun. 2026. GuruFocus rates FRA:3JR with a GF Score™ of 70/100 and a GF Value™ of €1.90 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Sopharma AD-Sofia's Non Operating Income for the three months ended in Jun. 2026 was €0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was €0 Mil.

Sopharma AD-Sofia Non Operating Income Related Terms

Sopharma AD-Sofia Non Operating Income Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Non Operating Income Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sopharma AD-Sofia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3JR
70GF Score
Sopharma AD-Sofia FRA:3JR
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €0 Mil mean?
Sopharma AD-Sofia (FRA:3JR) has a Non Operating Income of €0 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Non Operating Income too high?
Sopharma AD-Sofia's current Non Operating Income is €0 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Non Operating Income compare to MCK and COR?
Sopharma AD-Sofia's Non Operating Income of €0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Distribution company?
A good Non Operating Income depends on the Medical Distribution industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Non Operating Income is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.90, compared to a current price of €2.42 — trading 27.4% above its estimated fair value. The current Non Operating Income is €0 Mil. Sopharma AD-Sofia's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Non Operating Income is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued. The current stock price of €2.42 is trading 27.4% above its estimated GF Value™ of €1.90. GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.

Key valuation signals for FRA:3JR:

  • Non Operating Income: €0 Mil
  • GF Value™: €1.90 vs. price of €2.42 (27.4% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges SPH:PolandSFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
70GF Score

Get the complete analysis for FRA:3JR

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price
€1.90
GF Value